Oncolines will present three posters at the EORTC-NCI-AACR (ENA) Molecular Targets and Cancer Therapeutics conference that will be held in Barcelona (Spain) from October 23^rd to 25^th. On Wednesday, the first day of the conference, Daphne Kluitmans will present a new case study on the BTK inhibitor nemtabrutinib. BTK plays a key role in oncogenic B-cell signaling and is a molecular target for the development of therapies against various B-cell malignancies. Nemtabrutinib is a reversible inhibitor of both wild-type BTK and BTK mutants that are responsible for acquired clinical drug resistance against first-generation, irreversible BTK inhibitors such as ibrutinib. Currently, nemtabrutinib is in phase 3 clinical development for the treatment of B-cell cancers. The Oncolines^® cancer cell panel profiling, bioinformatics analyses and biochemical kinase profiling presented on the poster demonstrate how combined cellular and biochemical profiling can reveal previously underappreciated cross-reactivities and provide potential novel therapeutic applications of nemtabrutinib.

The new case study will be presented on a poster (abstract #67) entitled “Combined cellular and biochemical profiling of BTK inhibitor nemtabrutinib reveals potential application in BRAF-mutant cancers”, at poster board PB055.